AI assistant
Sending…
Propanc Biopharma, Inc. — Director's Dealing 2016
Sep 27, 2016
34906_dirs_2016-09-27_d3617227-e20c-42d9-8b63-0cd2330e225d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Propanc Health Group Corp (PPCH)
CIK: 0001517681
Period of Report: 2015-02-04
Reporting Person: Kenyon Julian Norman (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-02-04 | Common Stock, par value $0.001 | J | 17654470 | — | Acquired | 28466534 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-04-14 | Stock Option (Right to Buy) | $.03 | A | 71500000 | Acquired | 2021-04-14 | Common Stock, par value $0.001 (71500000) | Direct |
Footnotes
F1: These shares were issued to Dr. Kenyon pursuant to a Debt Settlement Agreement with the Issuer dated 2/4/15 in satisfaction of approximately $17,654 due to him in connection with certain non-interest bearing loans.
F2: This option vests as follows: 23,833,333 shares on 4/14/16, 23,833,333 shares on 4/14/17 and 23,833,334 shares on 4/14/18.
More from Propanc Biopharma, Inc.
Interim / Quarterly Report
2026
May 14
Capital/Financing Update
2026
Apr 10
Proxy Solicitation & Information Statement
2026
Mar 19
Board/Management Information
2026
Feb 26
Interim / Quarterly Report
2026
Feb 17
Capital/Financing Update
2026
Feb 2
Delisting Announcement
2026
Jan 7
Capital/Financing Update
2025
Dec 30
Proxy Solicitation & Information Statement
2025
Dec 29
Declaration of Voting Results & Voting Rights Announcements
2025
Dec 10